IGF-1 LR3 – Research Compound Profile

IGF-1 LR3 – Research Compound Profile

Category: Hormonal Research | Molecular Type: Synthetic Recombinant Protein (83 Amino Acids, ~9.1 kDa) | Research Status: Investigational — Not FDA-Approved

This page compiles published research data for qualified researchers. IGF-1 LR3 is sold exclusively as a research compound, is not approved for human use, and this page does not constitute medical advice.

Purchase for Research →

Molecular Overview

IGF-1 LR3 (Long Arginine 3 Insulin-like Growth Factor-1) is a synthetic analogue of human insulin-like growth factor-1, consisting of 83 amino acids compared to the 70 of native IGF-1. The compound is engineered with a 13-amino-acid N-terminal extension (MFPAMPLSSLFVN) and an arginine-for-glutamic-acid substitution at position 3 [4]. These structural modifications fundamentally alter the peptide’s interaction with IGF-binding proteins (IGFBPs), reducing IGFBP binding affinity by an estimated 100- to 1,000-fold compared to native IGF-1 [12].

In circulation, approximately 98% of native IGF-1 is sequestered by one of six IGFBPs, which regulate bioavailability and restrict receptor access [3]. Because IGF-1 LR3 largely evades this binding, nearly all of the compound remains in the free, receptor-available form in in vivo research models. Published data indicate a substantially extended functional half-life for IGF-1 LR3 compared to the minutes-scale half-life typical of unbound native IGF-1, and correspondingly greater in vivo potency [1] [2].

The seven cysteine residues of the IGF-1 domain form three intramolecular disulfide bonds (Cys6–Cys48, Cys18–Cys61, Cys47–Cys52 in native IGF-1 numbering) that stabilize the compact globular fold shared with proinsulin and IGF-2, placing IGF-1 LR3 structurally within the insulin/relaxin superfamily. Correct disulfide pairing during recombinant expression and refolding is essential for receptor engagement; mispaired or reduced disulfides are a recognized source of inactive protein in poorly manufactured lots [3].

Mechanism of Action

IGF-1 LR3 binds to the IGF-1 receptor (IGF-1R), a transmembrane tyrosine kinase receptor expressed on virtually every cell type. Receptor engagement triggers autophosphorylation of the intracellular beta subunits, initiating two primary downstream signaling cascades [9] [13]:

PI3K/Akt/mTOR Pathway: In skeletal muscle tissue, PI3K/Akt activation phosphorylates mTOR, which in turn stimulates p70S6K and 4E-BP1 — key regulators of ribosomal biogenesis and cap-dependent mRNA translation. This pathway drives protein synthesis, cell survival, and hypertrophy signaling. Simultaneously, Akt inhibits the FoxO family of transcription factors, suppressing muscle atrophy gene expression (MuRF-1, atrogin-1/MAFbx) [14]. This dual action — anabolic promotion plus anti-catabolic protection — has been documented in the preclinical literature as a central mechanism underlying IGF-1 LR3’s effects on muscle tissue in research models.

Raf/MEK/ERK Cascade: This pathway promotes cellular proliferation and differentiation. In the context of skeletal muscle, IGF-1 signaling through the IGF-1R activates satellite cells — the resident stem cells responsible for post-injury repair and adaptive growth. IGF-1 promotes satellite cell proliferation, differentiation into myoblasts, and subsequent fusion with existing myofibers [15].

Insulin Receptor Cross-Reactivity: IGF-1 LR3 shares structural homology with insulin and can bind to insulin receptors, albeit at lower affinity. This cross-reactivity accounts for insulin-like metabolic effects — enhanced glucose uptake and suppressed hepatic gluconeogenesis — which have been documented as a significant safety consideration in IGF-1-class compound research [10].

Published Research Parameters

The following table indexes the study models, durations, and reported observations of selected peer-reviewed publications. Dose, frequency, and administration-route details are deliberately omitted. This is a bibliographic index only — not a protocol and not a recommendation for any use.

Stability & Storage Characteristics

Published data on IGF-1 LR3 stability and storage conditions from manufacturer technical specifications and research literature:

• Lyophilized stability: The lyophilized powder has been reported stable at −20 °C (−4 °F) for up to 12 months, with optimal long-term storage at −80 °C (−112 °F). Short-term storage at 2–8 °C (35.6–46.4 °F) is considered acceptable for several months [7].
• Solution stability: Once reconstituted, the solution has been characterized as stable at 2–8 °C (35.6–46.4 °F) for up to 4 weeks. Sterile aliquots frozen at −20 °C (−4 °F) have been reported stable for 3–6 months. Repeated freeze-thaw cycles are documented to cause protein degradation and should be avoided [7].
• Protein integrity: As a recombinant protein, IGF-1 LR3 is susceptible to denaturation through mechanical agitation, excessive heat, and prolonged light exposure. Published handling guidance recommends gentle mixing (swirling rather than vortexing) and storage in opaque containers or foil-wrapped vials [7].
• Aggregation and adsorption: Recombinant single-chain proteins of this size are prone to surface adsorption at low concentration and to non-covalent aggregation on repeated handling; carrier-protein-free formulations are correspondingly more sensitive to these losses than formulations containing a stabilizing excipient.
• Visual inspection criteria: Reconstituted recombinant IGF-1 solutions should appear clear and colorless; solutions that are cloudy, contain visible particles, or show discoloration should be considered compromised, consistent with general recombinant-protein handling guidance published for this drug class [10].

Analytical Characterization

Research-grade IGF-1 LR3 lots are characterized with an orthogonal panel appropriate to a ~9.1 kDa recombinant single-chain protein. Reverse-phase HPLC and/or SDS-PAGE assess purity and detect truncation, aggregation, or misfolded species. Intact-mass confirmation by ESI-MS or MALDI-TOF verifies the expected monoisotopic/average mass corresponding to the 83-residue sequence with three correctly paired disulfide bonds; a mass shift of approximately 6 Da relative to the fully oxidized (disulfide-bonded) species can indicate incomplete oxidation or a free-thiol impurity. Bioactivity is frequently benchmarked against a cell-based IGF-1R phosphorylation or proliferation assay, since correct folding — not just correct primary sequence — determines receptor engagement. Endotoxin testing (LAL assay) is standard for recombinant proteins intended for cell-culture or in vivo research use. Researchers should retain the quality assurance documentation for each lot.

Key Published Research Findings

The following findings are derived from peer-reviewed publications investigating IGF-1 and its analogues. Each finding is attributed to its source study.

• Anabolic potency and muscle wasting reversal: In a 1992 Biochemical Journal study using dexamethasone-treated rats, Tomas et al. demonstrated that IGF-1 LR3 reversed glucocorticoid-induced muscle wasting and was significantly more potent than native IGF-1 in promoting nitrogen retention, establishing the enhanced bioactivity conferred by reduced IGFBP binding [1].

• Sustained bioactivity independent of administration method: In a 1996 Journal of Endocrinology study, Tomas et al. confirmed that IGF-I analogues with low IGFBP binding maintained their superior anabolic potency across the administration methods studied in rat models, indicating that the extended functional half-life permits sustained receptor activation [2].

• PI3K/Akt/mTOR-mediated protein synthesis: A 2019 Frontiers in Nutrition review by Yoshida and Delafontaine described the central role of the IGF-1/PI3K/Akt/mTOR signaling cascade in skeletal muscle protein synthesis, ribosomal biogenesis, and the regulation of anabolic resistance in aging skeletal muscle [9].

• Anti-catabolic mechanisms via FoxO inhibition: In a 2004 study published in Molecular Cell, Sandri et al. demonstrated that the IGF-1/PI3K/Akt pathway inhibits FoxO-mediated transcription of muscle-specific ubiquitin ligases (MuRF-1, MAFbx/atrogin-1), providing direct protection against proteolysis and muscle atrophy in myotube models [14].

• Satellite cell activation and muscle regeneration: A 2020 review by Ascenzi et al. in Cells documented that IGF-1 receptor signaling stimulates quiescent satellite cell proliferation and differentiation — a prerequisite for muscle fiber repair and adaptive hypertrophy following mechanical loading or injury in the models studied [15].

• Connective tissue and nerve repair: A 2021 Frontiers in Bioengineering and Biotechnology review described IGF-1’s role in stimulating fibroblast proliferation and collagen synthesis, supporting connective tissue remodeling and peripheral nerve repair in the preclinical literature beyond effects observed in skeletal muscle [16].

• Cardiovascular plaque stabilization: In a 2011 study published in the American Journal of Pathology, von der Thüsen et al. demonstrated that IGF-1 LR3 exerted plaque-stabilizing effects in atherosclerotic mouse models by modulating vascular smooth muscle cell phenotype toward a more stable, differentiated state [17].

• IGF-1/Akt pathway in skeletal muscle growth regulation: A 2011 Journal of Cellular Physiology review by Schiaffino and Mammucari synthesized evidence from genetic models demonstrating that the IGF-1/Akt/PKB pathway is a primary regulator of skeletal muscle growth, with both hypertrophic and anti-atrophic signaling components [13].

Safety Profile in Published Literature

Safety data for IGF-1 LR3 is primarily extrapolated from clinical studies of mecasermin (recombinant human IGF-1, marketed as Increlex®) and preclinical literature on IGF-1 analogues.

• Hypoglycemia: The most clinically significant adverse effect documented across IGF-1-class compounds. The Increlex prescribing label reports hypoglycemia in a substantial proportion of treated subjects, with symptoms including tremor, sweating, tachycardia, confusion, and in severe cases, loss of consciousness. The mechanism involves IGF-1’s suppression of hepatic glucose production and enhancement of peripheral glucose uptake [10].

• Injection site reactions: Localized erythema, swelling, and pruritus have been reported as common occurrences with subcutaneous protein administration in clinical trials of recombinant IGF-1 [10].

• Fluid retention and edema: IGF-1’s renal sodium-retaining properties have been associated with mild water retention in clinical trial populations, particularly at higher exposure levels. Periorbital and peripheral edema were reported in mecasermin clinical trials [10].

• Headache and musculoskeletal discomfort: Headache and jaw/joint pain were reported in clinical studies of recombinant IGF-1, considered likely related to tissue growth stimulation. These effects were characterized in the clinical literature as dose-dependent and transient [10].

• Long-term oncologic considerations: Chronic elevation of endogenous IGF-1 levels has been epidemiologically associated with increased risk of certain malignancies in observational studies, though this data reflects endogenous circulating IGF-1 levels rather than exogenous short-term administration [3]. The long-term safety profile of IGF-1 LR3 specifically has not been established in controlled clinical trials.

• Toxicology limitations: No comprehensive toxicology studies specific to IGF-1 LR3 have been published. Safety extrapolation relies on the mecasermin clinical program and preclinical IGF-1 analogue data, which may not fully represent the risk profile of the LR3 variant given its substantially greater potency and extended half-life.

Interpretive Limits

Nearly all of the human safety data cited above derives from mecasermin (a distinct, shorter-half-life recombinant IGF-1 molecule approved for a narrow pediatric indication), not from controlled human studies of IGF-1 LR3 itself. Given the substantially altered pharmacokinetics of the LR3 modification, extrapolating mecasermin’s clinical safety profile directly onto IGF-1 LR3 is not supported by the cited data and should be treated as a hypothesis-generating comparison only.

Regulatory Status

• FDA approval: IGF-1 LR3 has not been approved by the FDA for any human use. The only FDA-approved recombinant IGF-1 product is mecasermin (Increlex®), approved for a specific rare pediatric growth disorder [10]. This regulatory history is noted for completeness only and does not apply to the research compound described on this page.
• WADA classification: IGF-1 LR3 is classified as a prohibited substance by the World Anti-Doping Agency (WADA) under the category of peptide hormones and growth factors.
• Clinical trial status: No registered clinical trials evaluating IGF-1 LR3 specifically for any human indication have been identified on ClinicalTrials.gov.
• Research use only: IGF-1 LR3 is sold exclusively as a research compound for in vitro and preclinical investigation. It is not intended for human consumption, veterinary use, or diagnostic purposes.

References

1. Biochemical Journal (1992) — Tomas FM, Knowles SE, Owens PC, et al. “Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats.” Biochem J. 282(Pt 1):91-97. View Source

2. Journal of Endocrinology (1996) — Tomas FM, Lemmey AB, Read LC, Ballard FJ. “Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection.” J Endocrinol. 150(1):77-84. View Source

3. Biomolecules / MDPI (2021) — Bailes J, Soloviev M. “Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports.” Biomolecules. 11(2):217. View Source

4. Wikipedia — “IGF-1 LR3.” Comprehensive summary of structural modifications, pharmacokinetics, and amino acid sequence. View Source

7. ProSpec Bio — “Recombinant Human LR3 IGF-1: Product Technical Specifications.” Storage and stability data for research-grade IGF-1 LR3. View Source

9. Frontiers in Nutrition (2019) — Yoshida T, Delafontaine P. “The Role of the IGF-1 Signaling Cascade in Muscle Protein Synthesis and Anabolic Resistance in Aging Skeletal Muscle.” View Source

10. FDA / Increlex Label (2025) — “INCRELEX® (mecasermin) injection, for subcutaneous use.” Full prescribing information including pharmacology, adverse reactions, and warnings. View Source

12. Journal of Endocrinology (2002) — Mohan S, Baylink DJ. “IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms.” J Endocrinol. 175(1):19-31. View Source

13. Journal of Cellular Physiology (2011) — Schiaffino S, Mammucari C. “Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models.” J Cell Physiol. View Source

14. Molecular Cell (2004) — Sandri M, Sandri C, Gilbert A, et al. “Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.” / “The IGF-1/PI3K/Akt Pathway Prevents Expression of Muscle Atrophy-Induced Ubiquitin Ligases by Inhibiting FOXO Transcription Factors.” View Source

15. Cells / MDPI (2020) — Ascenzi F, Barberi L, Dobrowolny G, et al. “Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy.” Cells. 9(9):1970. View Source

16. Frontiers in Bioengineering and Biotechnology (2021) — “Insulin-Like Growth Factor-1: A Promising Therapeutic Target for Peripheral Nerve Injury.” Review of IGF-1’s role in nerve repair and connective tissue regeneration. View Source

17. American Journal of Pathology (2011) — von der Thüsen JH, et al. “IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype.” Am J Pathol. 178(2):924-34. View Source

⚠️ Disclaimer: This page is provided for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. IGF-1 LR3 is sold exclusively as a research compound, has not been approved by the FDA for human consumption, and is not intended for human use or self-administration. All information is derived from published peer-reviewed literature. Research must comply with all applicable laws, regulations, and institutional guidelines.

Purchase IGF-1 LR3 for Research →